Andrew L. Coveler
A5060994391- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Wnt/β-catenin signaling in development and cancer
- Pancreatic and Hepatic Oncology Research
- Glycogen Storage Diseases and Myoclonus
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
- Neuroendocrine Tumor Research Advances
- Carbohydrate Chemistry and Synthesis
- HER2/EGFR in Cancer Research
- Cancer Research and Treatments
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Glycosylation and Glycoproteins Research
- Colorectal and Anal Carcinomas
- Cancer Cells and Metastasis
- Cancer Treatment and Pharmacology
- Proteoglycans and glycosaminoglycans research
- Cancer, Hypoxia, and Metabolism
- Colorectal Cancer Surgical Treatments
- Economic and Financial Impacts of Cancer
- Ethics in Clinical Research
- Advanced Breast Cancer Therapies
University of Washington
2016-2025
Fred Hutch Cancer Center
2014-2025
University of Washington Medical Center
2013-2024
Cancer Research Center
2009-2024
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa
2021-2024
Seattle Cancer Care Alliance
2015-2022
Seattle University
2017-2022
University of Michigan
2016-2021
Centro de Investigación del Cáncer
2021
Monash Medical Centre
2018
No therapies for targeting
PURPOSE Prospective data on the efficacy of a watch-and-wait strategy to achieve organ preservation in patients with locally advanced rectal cancer treated total neoadjuvant therapy are limited. METHODS In this prospective, randomized phase II trial, we assessed outcomes 324 stage or III adenocarcinoma induction chemotherapy followed by chemoradiotherapy (INCT-CRT) consolidation (CRT-CNCT) and either mesorectal excision (TME) basis tumor response. Patients both groups received 4 months...
Data suggest selective internal radiotherapy (SIRT) in third-line or subsequent therapy for metastatic colorectal cancer has clinical benefit patients with liver metastases liver-dominant disease after chemotherapy. The FOXFIRE, SIRFLOX, and FOXFIRE-Global randomised studies evaluated the efficacy of combining first-line chemotherapy SIRT using yttrium-90 resin microspheres metastases. were designed combined analysis overall survival.
The primary objectives of this phase I/II study were to evaluate the safety and immunogenicity combination therapy consisting concurrent trastuzumab human epidermal growth factor receptor 2 (HER2)/neu-specific vaccination in patients with HER2/neu-overexpressing metastatic breast cancer.Twenty-two stage IV HER2/neu-positive cancer receiving vaccinated an HER2/neu T-helper peptide-based vaccine. Toxicity was graded according National Cancer Institute criteria, antigen specific T-cell immunity...
KRAS p.G12C mutation occurs in approximately 1 to 2% of pancreatic cancers. The safety and efficacy sotorasib, a G12C inhibitor, previously treated patients with p.G12C–mutated cancer are unknown.
JCO
Importance Assessing clinical tumor response following completion of total neoadjuvant therapy (TNT) in patients with locally advanced rectal cancer is paramount to select for watch-and-wait treatment. Objective To assess organ preservation (OP) and oncologic outcomes according grade. Design, Setting, Participants This was secondary analysis the Organ Preservation Patients Rectal Adenocarcinoma trial, a phase 2, nonblinded, multicenter, randomized trial. Randomization occurred between April...
// C. Willemien Menke-van der Houven van Oordt 1 , Carlos Gomez-Roca 2 Carla Herpen 3 Andrew L. Coveler 4 Devalingam Mahalingam 5 Henk M. W. Verheul Winette T. A. Graaf Randolph Christen 6 Dominik Rüttinger 7 Stefan Weigand Michael Cannarile Florian Heil Brewster 8 Antje-Christine Walz 9 Tapan K. Nayak Ernesto Guarin Valerie Meresse and Christophe Le Tourneau 10 Department of Medical Oncology, VU University Center, Amsterdam, The Netherlands Clinical Research Unit, Institut Claudius Regaud,...
We previously demonstrated vast expansion of hypoxic areas in the leukemic microenvironment and provided a rationale for using hypoxia-activated prodrugs. PR104 is phosphate ester that rapidly hydrolyzed vivo to corresponding alcohol PR-104A further reduced amine hydroxyl-amine nitrogen mustards induce DNA cross-linking cells under low oxygen concentrations. In this phase I/II study, patients with relapsed/refractory acute myeloid leukemia (n=40) after 1 or 2 prior treatments lymphoblastic...
<h3>Importance</h3> Salvage chemotherapy for recurrent chest wall lesions in breast cancer results response rates of 20% to 30%. Preclinical studies showed significant disease regression could be induced murine mammary cancers with a topical toll-like receptor (TLR)-7 agonist, imiquimod. <h3>Objective</h3> To evaluate the safety and objective rate (ORR) imiquimod combination systemic albumin bound paclitaxel treatment-refractory wall. <h3>Design, Setting, Particpants</h3> A single arm phase...
High levels of ERBB2 (formerly HER2)-specific type 1 T cells in the peripheral blood are associated with favorable clinical outcomes after trastuzumab therapy; however, only a minority patients develop measurable immunity treatment. Vaccines designed to increase ERBB2-specific T-helper could induce majority patients.
360490 Background: KRAS mutation is present in 90% of pancreatic ductal adenocarcinomas with p.G12C accounting for 1% to 2% these mutations. Sotorasib, a small molecule that specifically and irreversibly inhibits G12C , has been investigated the CodeBreaK100 trial patients -mutated advanced solid tumors. Herein, we report on largest dataset evaluating efficacy safety inhibitor pretreated cancer. Methods: (NCT03600883) an international, single arm, phase I/II study sotorasib tumors ≥ 1 prior...
Pancreatic ductal adenocarcinoma (PDA) remains a deadly disease that is rarely cured, despite many recent successes with immunotherapy for other malignancies. As the human heavily infiltrated by effector T cells, we postulated accurately modeling PDA immune microenvironment would allow us to study mechanisms of immunosuppression could be overcome therapeutic benefit. Using viable precision-cut slices from fresh PDA, developed an organotypic culture system this purpose. We confirmed cultured...
Abstract Purpose: Duligotuzumab is a dual-action antibody directed against EGFR and HER3. Experimental Design: Metastatic colorectal cancer (mCRC) patients with KRAS ex2 wild-type received duligotuzumab or cetuximab FOLFIRI until progression intolerable toxicity. Mandatory tumor samples underwent mutation biomarker analysis. Efficacy analysis was conducted in RAS exon 2/3 tumors. Results: Of 134 randomly assigned patients, 98 had ex2/3 wild-type. provided no progression-free survival (PFS)...
Abstract Purpose: CD44, a cell surface glycoprotein, plays important roles in the development, progression, and metastasis of various tumor types. The aim this study was to investigate how expression CD44 isoforms influences interaction with hyaluronic acid (HA) differential isoform impacts antitumoral responses vivo treatment RG7356, humanized anti-CD44 antibody inhibiting CD44–HA interaction. Experimental Design: on lines analyzed by RNASeq while data patients different types were obtained...
Objectives: To compare the efficacy and safety of algenpantucel-L [HyperAcute-Pancreas (HAPa); IND# 12311] immunotherapy combined with standard care (SOC) chemotherapy chemoradiation to SOC therapy alone in patients borderline resectable or locally advanced pancreatic ductal adenocarcinoma (PDAC). Summary Background Data: date, has not been shown benefit unresectable PDAC. HAPa is a cancer vaccine consisting allogeneic cells engineered express murine α(1,3)GT gene. Methods: A multicenter,...
3509 Background: Clinical response following neoadjuvant therapy is paramount to identifying locally advanced rectal cancer (LARC) patients suitable for Watch and Wait (WW). A 3-tier schema was devised stratify clinical response. Patients with a complete (cCR) are considered WW, while those an incomplete (iCR) recommended total mesorectal excision (TME). near (nCR) tier captures significant, but not complete, be WW. This schema’s efficacy has yet validated. We investigated survival organ...
Despite the occurrence of HER2 amplification/overexpression (HER2+) in ~3% to 5% all patients with metastatic colorectal cancer (mCRC) and up ~10% RAS/BRAF wild-type mCRC, there are currently no FDA- or EMA-approved HER2-directed therapies for HER2+ mCRC. Patients mCRC who progress on early lines chemotherapy regimens receive limited clinical benefit from current standard-of-care treatments. Tucatinib is a highly selective, HER2-directed, tyrosine kinase inhibitor. The MOUNTAINEER trial...
SEA-CD40 is an investigational, non-fucosylated, humanized monoclonal IgG1 antibody that activates CD40, immune-activating tumor necrosis factor receptor superfamily member. exhibits enhanced binding to activating FcγRIIIa, possibly enabling greater immune stimulation than other CD40 agonists. A first-in-human phase 1 trial was conducted examine safety, pharmacokinetics, and pharmacodynamics of monotherapy in patients with advanced solid tumors lymphoma. administered intravenously or...
Recent trials suggest that programmed cell death 1 (PD-1)-directed immunotherapy may be beneficial for some patients with anal squamous carcinoma and biomarkers predictive of response are greatly needed. This multicenter phase II clinical trial (NCT02919969) enrolled metastatic or locally advanced incurable (n=32). Patients received pembrolizumab 200 mg every 3 weeks. The primary endpoint the was objective rate (ORR). Exploratory objectives included analysis potential including assessment...